Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...
News Medical on MSN11h
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
pharmaphorum13h
Tirzepatide gets a big win in obesity-related heart failure
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...